Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × OTHER_GOV × durvalumab × Clear all

Phase

Phase 2 3 Phase 3 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 64 OTHER 9 NIH 4 NETWORK 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Neoplasm Metastasis 1

Interventions

Radiotherapy 9 Carboplatin 7 Cisplatin 6 Capecitabine 6 Neoadjuvant Therapy 5 Gemcitabine 5 Fluorouracil 5 Docetaxel 5 Paclitaxel 4 Cyclophosphamide 4 Trastuzumab 3 Tamoxifen 3 Oxaliplatin 3 Hydralazine 3 Etoposide 3 Drug Therapy 3 pertuzumab 2 pegylated granulocyte colony-stimulating factor 2 palbociclib 2 Valproic Acid 2 Tranexamic Acid 2 Temozolomide 2 TP protocol 2 Surgical Procedures, Operative 2 Saline Solution 2 Radiotherapy, Adjuvant 2 Radiation 2 Proton Pump Inhibitors 2 Pemetrexed 2 Nivolumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡